TY - JOUR
T1 - Advances in the pathogenesis and treatment of thyroid cancer
AU - Hanna, Nader N.
AU - McGrath, Patrick C.
AU - Sloan, David A.
AU - Kenady, Daniel E.
PY - 1999
Y1 - 1999
N2 - Thyroidectomy remains the mainstay of treatment for thyroid carcinoma. The extent of surgical resection, however, remains controversial as most patients will have excellent long-term prognosis and because some of the standard staging and prognostic information are not available at the time of surgical resection. The different staging and risk group definitions for thyroid carcinoma are not superior to the Tumor-Node-Metastasis classification of the American Joint Commission in Cancer (AJCC), which is universally available and accepted and should be used to report treatment outcomes. Recent advances in the molecular pathogenesis of thyroid malignancy will help identify high-risk patients who would benefit from aggressive surgical resection and adjuvant treatment.
AB - Thyroidectomy remains the mainstay of treatment for thyroid carcinoma. The extent of surgical resection, however, remains controversial as most patients will have excellent long-term prognosis and because some of the standard staging and prognostic information are not available at the time of surgical resection. The different staging and risk group definitions for thyroid carcinoma are not superior to the Tumor-Node-Metastasis classification of the American Joint Commission in Cancer (AJCC), which is universally available and accepted and should be used to report treatment outcomes. Recent advances in the molecular pathogenesis of thyroid malignancy will help identify high-risk patients who would benefit from aggressive surgical resection and adjuvant treatment.
UR - http://www.scopus.com/inward/record.url?scp=0033042467&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033042467&partnerID=8YFLogxK
U2 - 10.1097/00001622-199901000-00010
DO - 10.1097/00001622-199901000-00010
M3 - Review article
C2 - 9914877
AN - SCOPUS:0033042467
SN - 1040-8746
VL - 11
SP - 42
EP - 47
JO - Current Opinion in Oncology
JF - Current Opinion in Oncology
IS - 1
ER -